Sujal Shah
Overview
Sujal Shah received an average of $2M in total compensation, including $410K in salary, at Cymabay Therapeutics from 2013 to 2022.
2022Cymabay TherapeuticsChief Executive Officer
2021Cymabay TherapeuticsChief Executive Officer
2020Cymabay TherapeuticsChief Executive Officer
2019Cymabay TherapeuticsChief Executive Officer
2018Cymabay TherapeuticsPresident and Chief Executive Officer
2017Cymabay TherapeuticsPresident and Chief Executive Officer
2015Cymabay TherapeuticsChief Financial Officer
2014Cymabay TherapeuticsChief Financial Officer
2013Cymabay TherapeuticsChief Financial Officer
Source: SEC filings on April 19, 2023, April 26, 2022, May 15, 2020, April 26, 2019, April 20, 2018, April 21, 2016, and April 21, 2015.
Related executives
We found nine more executives who work or worked at Cymabay Therapeutics.
Charles McWherter
Cymabay Therapeutics
President of R&D
Paul Quinlan
Cymabay Therapeutics
General Counsel
Dennis Kim
Cymabay Therapeutics
Chief Medical Officer
Lewis Stuart
Cymabay Therapeutics
Chief Commercial Officer
Janet Dorling
Cymabay Therapeutics
Former Chief Commercial Officer
Pol Boudes
Cymabay Therapeutics
Chief Medical Officer
Klara Dickinson
Cymabay Therapeutics
Chief Regulatory and Compliance Officer
Daniel Menold
Cymabay Therapeutics
Vice President, Finance
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019